Kyntra Bio Inc (NASDAQ:KYNB) Stock Has Average Price Target of $36.80

Kyntra Bio Inc (NASDAQ:KYNB) has received a consensus recommendation of “Hold” from the seven research firms that are presently covering the company, MarketBeat reports. Two investment analysts have rated the stock with a sell rating and five have issued a buy rating on the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $36.80.

KYNB has been the subject of several recent analyst reports. Lake Street Capital assumed coverage on Kyntra Bio in a research note on Thursday, September 17th. They issued a “buy” rating and a $41.00 price target for the company. Maxim Group began coverage on Kyntra Bio in a research report on Tuesday, October 13th. They set a “buy” rating and a $35.00 price target on the stock. HC Wainwright reissued a “buy” rating and issued a $43.00 price objective on shares of Kyntra Bio in a report on Tuesday, September 1st. Weiss Ratings raised Kyntra Bio from a “sell (d)” rating to a “sell (d+)” rating in a report on Monday, October 26th. Finally, Zacks Research cut Kyntra Bio from a “hold” rating to a “strong sell” rating in a research report on Monday, October 12th.

Kyntra Bio Stock Up 1.9%

KYNB stock opened at $3.73 on Friday. The company’s 50-day simple moving average is $6.29 and its 200-day simple moving average is $7.00. Kyntra Bio has a 52-week low of $3.60 and a 52-week high of $11.39. The firm has a market cap of $15.11 million, a P/E ratio of 0.08 and a beta of 1.08.

Institutional Investors Weigh In On Kyntra Bio

A hedge fund recently bought a new stake in Kyntra Bio stock. ADAR1 Capital Management LLC purchased a new position in Kyntra Bio Inc (NASDAQ:KYNB) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 10,469 shares of the company’s stock, valued at approximately $71,000. ADAR1 Capital Management LLC owned approximately 0.26% of Kyntra Bio as of its most recent filing with the Securities and Exchange Commission. 72.71% of the stock is owned by institutional investors.

Kyntra Bio Company Profile

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes.